You are here

Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline & Trials

Oncology Pipeline Snapshot as of October 30, 2018

  • Discovery Projects
  • Phase 1
    17
  • Phase 2
    7
  • Phase 3
    17
  • Registration
    4
  • Total45
 
Compound Name
Indication
Phase
Submission Type
Compound Typesort descending
glasdegib (PF-04449913)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/ low-dose cytarabine (LDAC) for: Acute Myeloid Leukemia (PRIORITY REVIEW) Registration New Molecular Entity Small Molecule
dacomitinib (PF-00299804)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
pan-HER Inhibitor
Go to clinical trial
1st Line EGFR-activating mutant Non-Small Cell Lung Cancer (E.U.) Registration New Molecular Entity Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
Cancer Phase 1 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
Early Breast Cancer in Adjuvant Setting Phase 3 Product Enhancement Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic High Risk Hormone Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
talazoparib (MDV3800)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
PARP inhibitor
Go to clinical trial
2nd Line Metastatic Castration-Resistant Prostate Cancer Phase 2 Product Enhancement Small Molecule
talazoparib (MDV3800)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Germline BRCA Mutated Metastatic Breast Cancer (E.U.) Registration New Molecular Entity Small Molecule
PF-06952229
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor
Go to clinical trial
Cancer
Project advanced
Phase 1 New Molecular Entity Small Molecule
lorlatinib (PF-06463922)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
lorlatinib (PF-06463922)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
2nd Line ALK Non-Small Cell Lung Cancer (BREAKTHROUGH, ORPHAN - U.S., PRIORITY REVIEW) Registration New Molecular Entity Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
HER2+ Breast Cancer Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
High Risk Early Breast Cancer Phase 3 Product Enhancement Small Molecule
talazoparib (MDV3800)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Combo w/ Xtandi (enzalutamide) for: 1st Line Metastatic Castration-Resistant Prostate Cancer Phase 3 Product Enhancement Small Molecule
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
CDK inhibitor
Go to clinical trial
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
Inlyta (axitinib)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
VEGF Tyrosine Kinase Inhibitor
Go to clinical trial
Combo w/ Merck's Keytruda (PD-1, pembrolizumab) for: Cancer Phase 1 Product Enhancement Small Molecule
glasdegib (PF-04449913)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Cancer Phase 1 Product Enhancement Small Molecule
PF-06821497
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
EZH2 inhibitor
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
glasdegib (PF-04449913)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Small Molecule
Select one or more conditions listed below. You can also enter your location (city, state, and/or Zip code) to find a trial near you.Clear Options